Sequence to Solution: Synthetic DNA Accelerating Advanced Therapies

Watch our on-demand Webinar

Discover how synthetic DNA is transforming advanced therapies, enabling faster development of personalized cancer vaccines and mRNA treatments from sequence to clinic.

Bringing together two pioneering companies, Neomatrix Biotech and HelixNano, this webinar features insights from Luigi Aurisicchio, CEO, and Marianna Keaveney, CSO, as they share how synthetic DNA is powering their development pipelines and accelerating therapeutic innovation.

Speakers

Luigi Aurisicchio, CEO at Neomatrix Biotech
Discusses breakthrough work in personalized cancer vaccines and how synthetic DNA enables rapid translation of patient-specific tumour antigens into clinical candidates.

Marianna Keaveney, CSO at HelixNano
Shares insights on leveraging mRNA technology for infectious disease and cancer treatment, highlighting the importance of synthetic DNA quality in therapeutic performance.

You’ll learn:

• How synthetic DNA accelerates development timelines for personalized cancer vaccines and mRNA-based therapies

• The importance of DNA quality, sequence accuracy, and customization for successful clinical translation

• Real-world case studies demonstrating how development bottlenecks were overcome using synthetic DNA solutions

• Key technical advantages, including construct design flexibility, speed, and scalability